Navigation Links
Preventing or reducing enlarged heart may decrease risk for diabetes
Date:10/31/2007

NEW YORK (Oct. 31, 2007) -- High-blood-pressure patients treated for enlarged heart (left ventricular hypertrophy, LVH) who have regression or prevention of LVH may also have a better chance of preventing diabetes. Led by physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, the research is published in the November Hypertension, a journal of the American Heart Association (AHA).

An estimated 20 percent of all high-blood-pressure patients, or 12 million Americans, have LVH and are at increased risk of developing diabetes.

The study reports a 38-percent reduced risk of developing diabetes for high-blood-pressure patients who demonstrated regression of LVH during treatment for high blood pressure, with a 26-percent reduced risk after adjusting for other risk factors for diabetes. The reduction in risk of diabetes was independent of treatment type and of the degree of blood pressure change in this population.

"A healthy heart is a prerequisite for the health of the body as a whole. Our previous research has shown that treating enlarged heart in high-blood-pressure patients reduces the risk for a variety of cardiovascular conditions. This new study finds an important new benefit -- namely a better chance of avoiding diabetes among patients who exhibit a reduction of their hypertrophy during treatment," says the study's principal investigator, Dr. Peter Okin, director of clinical affairs and professor of medicine in the Greenberg Division of Cardiology at Weill Cornell Medical College and attending physician at NewYork-Presbyterian/Weill Cornell.

An editorial about the study in the journal notes that "the study by Okin et al extends our knowledge and understanding of the importance of LVH reversal by showing the beneficial metabolic effects of treatment-induced regression of LVH in a large series of patients with hypertensive heart disease."

Unfortunately, for high-blood-pressure patients wh
'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

1

GOOD

Page: 1 2

Related medicine news :

1. Preventing mental decline in the aged
2. Preventing white coat hypertension
3. Green tea beneficial in preventing osteoarthritis
4. Preventing Childhood Deaths
5. Preventing Vision Loss
6. Preventing Vision Loss
7. Preventing Colorectal Cancer
8. Preventing Prostate Cancer
9. Lycopene Can Help In Preventing Prostate Cancer
10. Heart Drug Also Effective In Preventing Specific Causes Of Death
11. Preventing cavities in children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2008)... Byetta has also been linked recently to patient d...s) -- A new once-a-week formulation of the injecta... better than the older twice-a-day formulation, re...ase of use, [the new formulation] provided the rem...cose control and good gastrointestinal tolerabilit...
(Date:9/5/2008)... HARRISBURG, Pa., Sept. 5 /PRNewswire-USNewswire/ ... issued a proclamation acknowledging Sept. 11 as,A...lth of Pennsylvania and The American Red Cross ask...oration of those who lost their,lives on 9/11 and ...lood,donation can save up to three lives., "We al...
(Date:9/5/2008)...earchers explain how theoretical ,anti-cloak, coul..., Sept. 5 (HealthDay News) -- Just in case someone...se scientists say they know how to uncloak the obj... in Optics Express , certain materials underneath...ts to be seen again. , Researchers at Shanghai ...
(Date:9/5/2008)... FRANKLIN, Mass., Sept. 5 /PRNewswire/ -- Arthrosu...developer of less-invasive joint,resurfacing syste...he U.S.,FDA to begin its pivotal investigation for...FDA stated that "there are no outstanding safety,c...tiation., Arthrosurface has been evaluating the s...
Breaking Medicine News(10 mins):Health News:Once-Weekly Diabetes Drug Boosts Blood Sugar Control 2Health News:Arthrosurface HemiCAP(R) Focal Knee Resurfacing Implant Receives FDA Approval to Move into Final Investigational Stage 2
...ge that victims of the terrible 'Elephant Man' cli... a 'reckless' rate.// The drug, a monoclonal anti...mia, multiple sclerosis and rheumatoid arthritis. ...t the victims had been injected 15 times faster th...
...lf of all children in the most rural counties of t...eas, according to a new study //by HHS Agency for ...published in the September-October 2006 issue of A... was led by AHRQ’s Frances Chevarley, Ph.D., analy...
...s can be treated with a low-priced antibiotic, acc...the limbs or scrotum. // A team of scientists at t...t doxycycline gave some relief to patients in the ...e. In addition, the antibiotic killed the causativ...
...earch has revealed that it is tougher to quit ment...be the reason for the excessive smoking-related di...lished in the Archives of Internal Medicine.Nearly...thol cigarettes like Kool or Newport in comparison...
Other Medicine News:Health News:Catastrophic Elephant Man Drug Trial Victims Injected Recklessly 2Health News:Local Health Care Limited for Rural Children 2Health News:Menthol cigarettes harder to quit than regular cigarettes 2
(Date:9/6/2008)...cent or Greater Concordance Compared to FISH ... - Company to Include Reporting for HER2 Gene Expr...eports by End of 2008 -, REDWOOD CITY, Calif., Se...c. (Nasdaq: GHDX ) today announced results from t...ng for HER2 gene expression, as measured by the,co...
(Date:9/5/2008)...PRNewswire-USNewswire/ -- The Florida,Technology, ...orida,Atlantic University researcher Dr. Herbert W...the Center for Molecular Biology and,Biotechnology... CHS,Resources LLC (CHS), $184,294 as part of the ...ance Grant program (SURECAG). SURECAG was,establis...
(Date:9/5/2008)..., Sept. 5 /- SARcode,Corpor... LFA-1 inhibitors,to treat inflammatory diseases, ...oday announced SARcode,s initiation of a Phase 1 c...ndidate for T-cell mediated ophthalmic,diseases. S...t providing,SARcode with an exclusive license to S...
(Date:9/4/2008)... 4 /- Cytopia Limited (ASX:,CYT) toda...s Phase Ib/II,study of CYT997, the company,s novel... with an aggressive form of brain cancer known as ...trial is the first Phase II efficacy study in high...ny and the second in its,suite of Phase II studies...
Breaking Medicine Technology:Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 2Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 3Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 4Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 5Major State Grant Accelerates Research and Development of Novel Cancer Therapy 2Major State Grant Accelerates Research and Development of Novel Cancer Therapy 3SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 2SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 3Cytopia Commences Second Phase II Study in Brain Cancer 2Cytopia Commences Second Phase II Study in Brain Cancer 3Medgate Selected by NASA to Deliver Health and Safety Software Solutions 23181 1Back From the Dead 3A Cardiac Arrest Victim Salutes His Rescuer 23177 1Back From the Dead 3A Cardiac Arrest Victim Salutes His Rescuer 23177 2Georgia to Offer More Community Living Alternatives for Individuals With Disabilities 23174 1Georgia to Offer More Community Living Alternatives for Individuals With Disabilities 23174 2Georgia to Offer More Community Living Alternatives for Individuals With Disabilities 23174 3New Hope Against the Cold Sore Virus 23170 1New Hope Against the Cold Sore Virus 23170 2New Hope Against the Cold Sore Virus 23170 3
Transcranial vascular DWL doppler.
Transcranial vascular DWL doppler.
Transcranil vascular DWL doppler.
...m Viasys Neurocare is a full-featured physiologic ...table size. It contains many of the features of ou...t an economical price. , ,The smaller size of ...ironment, the physician's office, a mobile service...
Medicine Products: